DiaMedica Inc.  

(Public, CVE:DMA)   Watch this stock  
Find more results for Rick Robbins
0.400
-0.020 (-4.76%)
Sep 23 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.40 - 0.42
52 week 0.35 - 1.40
Open 0.42
Vol / Avg. 24,740.00/21,725.00
Mkt cap 26.05M
P/E     -
Div/yield     -
EPS -0.11
Shares 62.03M
Beta 0.05
Inst. own     -
Aug 6, 2014
DiaMedica Inc at CFA Society of Minnesota's InvestMNt Conference
  

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -267.80% -228.01%
Return on average equity - -423.77%
CDP Score - -

Address

Suite 124, One Carlson Parkw
MINNEAPOLIS, MN 55447
United States - Map
+1-763-7104452 (Phone)
+1-204-4533745 (Fax)

Website links

Description

DiaMedica Inc. (DiaMedica) is a development-stage company. The Company is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. DiaMedica's compound, DM-199, is a recombinant human protein for the treatment of both Type I and Type II diabetes and their complications. DiaMedica is starting a Phase I/II clinical trial for DM-199. DM-199 is a recombinant human protein, which improves glucose control, protects beta cells through the expansion of a population of antigen-specific immunosuppressive cells (Tregs), and proliferates insulin producing beta cells through the activation of certain growth factors. The Company´┐Żs DM-204 is a G-protein-coupled receptor agonist (GPCR) monoclonal antibody to treat Type II diabetes and some of the associated complication's. activating a receptor resulted in insulin sensitivity, insulin secretion and vasodilation.

Officers and directors

Richard D. Pilnik Independent Chairman of the Board
Age: 56
Rick Pauls President, Chief Executive Officer, Director
John Savage Chief Financial Officer
James T. Parsons Vice President - Finance, Corporate Secretary
Mark Robbins Ph.D., J.D. Vice President - Clinical and Regulatory Affairs
Mark Williams Ph.D. Vice President - Research
Edward Rady Senior Consultant - Licensing and Partnering
Michael Giuffre MD Independent Director
Dawson J. Reimer Independent Director
Age: 43
Thomas G. Wellner Independent Director